Comparison of various EGFR tyrosine kinase inhibitors (TKIs) for tumors with exon 18 mutations of the EGFR gene

被引：0
|
作者：
Mitsudomi, Tetsuya [1 ]
Kobayashi, Yoshihisa [1 ]
Togashi, Yosuke [2 ]
Mizuuchi, Hiroshi [1 ]
Suda, Kenichi [1 ]
NIshio, Kazuto [2 ]
机构：
[1] Kinki Univ, Thorac Surg, Higashiosaka, Osaka 577, Japan
[2] Kinki Univ, Genome Biol, Higashiosaka, Osaka 577, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-10-1
引用
收藏
页码：83 / 83
页数：1
相关论文
共 50 条
  • [1] EGFR mutations and EGFR tyrosine kinase inhibitors
    Torri, Valter
    Broggini, Massimo
    Garassino, Marina Chiara
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : 746 - 748
  • [2] Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR
    Yasuda, Hiroyuki
    Sng, Natasha J.
    Yeo, Wee-Lee
    Figueiredo-Pontes, Lorena L.
    Kobayashi, Susumu
    Costa, Daniel B.
    [J]. CANCER RESEARCH, 2012, 72
  • [3] SENSITIVITY OF EGFR EXON 20 INSERTION MUTATIONS TO EGFR INHIBITORS IS DETERMINED BY THEIR LOCATION WITHIN THE TYROSINE KINASE DOMAIN OF EGFR
    Yasuda, Hiroyuki
    Figueiredo-Pontes, Lorena L. D.
    Tenen, Daniel G.
    Kobayashi, Susumu
    Costa, Daniel B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S107
  • [4] Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
    Kobayashi, Susumu
    Canepa, Hannah M.
    Bailey, Alexandra S.
    Nakayama, Sohei
    Yamaguchi, Norihiro
    Goldstein, Michael A.
    Huberman, Mark S.
    Costa, Daniel B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : 118 - 122
  • [5] Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR.
    Costa, Daniel Botelho
    Yasuda, Hiroyuki
    Sng, Natasha J.
    Yeo, Wee-Lee
    de Figueiredo-Pontes, Lorena Lobo
    Tenen, Daniel G.
    Kobayashi, Susumu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.
    Ai, Xinghao
    Chen, Rongrong
    Cui, Jiuwei
    Zhang, Jiexia
    Lin, Wen
    Xie, Congying
    Hu, Xiaohua
    Zhang, Junping
    Jiao, Xiaodong
    Rao, Chuangzhou
    Yang, Weihua
    Chang, Lianpeng
    Xia, Xuefeng
    Yi, Xin
    Lu, Shun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] EGFR mutations in squamous NSCLC - Prevalence and treatment results with EGFR tyrosine kinase inhibitors (TKIs) in patients from western Slovakia
    Berzinec, P.
    Hlinkova, K.
    Copakova, L.
    Konecny, M.
    Zavodna, K.
    Cerna, M.
    Culagova, M.
    Chowaniecova, G.
    Babal, P.
    [J]. LUNG CANCER, 2012, 77 : S21 - S21
  • [8] Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors
    Javadi, Samira
    Zhiani, Mina
    Mousavi, Mir Ali
    Fathi, Mojtaba
    [J]. EUROPEAN JOURNAL OF CELL BIOLOGY, 2020, 99 (04)
  • [9] Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors
    Thomas, R. K.
    Greulich, H.
    Yuza, Y.
    Lee, J. C.
    Tengs, T.
    Feng, W.
    Chen, T. -H.
    Nickerson, E.
    Simons, J.
    Echolm, M.
    Rothberg, J. M.
    Sellers, W. R.
    Meyerson, M. L.
    [J]. MOLECULAR APPROACHES TO CONTROLLING CANCER, 2005, 70 : 73 - 81
  • [10] Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics
    van Zandwijk, N
    [J]. LUNG CANCER, 2006, 51 (01) : 137 - 138
12345